After Shortage, Harrow Announces Relaunch of Triesence

Harrow has officially relaunched Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid. Triesence is approved by the FDA for use in visualizing tissues during vitrectomy and treating ocular inflammatory conditions that do not respond to topical corticosteroids.

“We are very excited to have brought Triesence back, providing ophthalmologists access to a trusted FDA-approved product that has benefited millions of Americans," Mark L. Baum, Chairman and CEO of Harrow, said in a company news release. "Accomplishing this required rebuilding the entire Triesence supply chain and involved a global collaboration between Harrow and technical experts from our partners around the world. We are grateful for this team’s dedication and commitment, without which we would not have achieved this success.”

The relaunch follows a prolonged shortage, with Triesence previously appearing on the FDA Drug Shortage List for more than 5 years. Its absence left many retina specialists relying on off-label alternatives.